Abstract
Continuing developments from the study of cancer at the molecular level are yielding increasing numbers of targets that may be used for therapeutic intervention. Advances in the field of antibody engineering over the past several decades have given scientists the capability of directing the highly specific interaction of antibodies with antigens inward, to the intracellular compartments of living cells. These intracellular antibodies, i.e., intrabodies, are being developed to bind to, neutralize, or modify the function or localization of cancer-related targets and thereby affect the malignant phenotype. This has resulted in a promising new tool for the study and treatment of cancer. Due to recent advances in the development of the antibody engineering technologies, increasing numbers of intrabodies are being exploited to a growing list of cancer-related, as well as other disease targets. There are still, however, many technical issues, particularly related to clinical applications of the intrabodies, that must be addressed before the full promise of this class of therapeutic agent is realized. This review will focus on the recent progress in the generation and use of intrabodies in the field of oncology. The technical issues associated with their further development will also be discussed.
Keywords: antibody-antigen interaction, RNA interference methods (RNAi), Intracellular Signal Transduction, Apoptosis, tumor-associated receptor
Current Medicinal Chemistry
Title: Intrabody-Based Approaches to Cancer Therapy: Status and Prospects
Volume: 13 Issue: 12
Author(s): Brent R. Williams and Zhenping Zhu
Affiliation:
Keywords: antibody-antigen interaction, RNA interference methods (RNAi), Intracellular Signal Transduction, Apoptosis, tumor-associated receptor
Abstract: Continuing developments from the study of cancer at the molecular level are yielding increasing numbers of targets that may be used for therapeutic intervention. Advances in the field of antibody engineering over the past several decades have given scientists the capability of directing the highly specific interaction of antibodies with antigens inward, to the intracellular compartments of living cells. These intracellular antibodies, i.e., intrabodies, are being developed to bind to, neutralize, or modify the function or localization of cancer-related targets and thereby affect the malignant phenotype. This has resulted in a promising new tool for the study and treatment of cancer. Due to recent advances in the development of the antibody engineering technologies, increasing numbers of intrabodies are being exploited to a growing list of cancer-related, as well as other disease targets. There are still, however, many technical issues, particularly related to clinical applications of the intrabodies, that must be addressed before the full promise of this class of therapeutic agent is realized. This review will focus on the recent progress in the generation and use of intrabodies in the field of oncology. The technical issues associated with their further development will also be discussed.
Export Options
About this article
Cite this article as:
Williams R. Brent and Zhu Zhenping, Intrabody-Based Approaches to Cancer Therapy: Status and Prospects, Current Medicinal Chemistry 2006; 13 (12) . https://dx.doi.org/10.2174/092986706776872899
DOI https://dx.doi.org/10.2174/092986706776872899 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Tissue-Based Approaches to Study Pharmacodynamic Endpoints in Early Phase Oncology Clinical Trials
Current Drug Targets Novel 3-(1-(2-(2,7a-dihydrobenzo[d]thiazol-2-ylthio)acetyl)-5-substitutedphenyl-4,5-dihydro-1H-pyrazol-3-yl)-Coumarins: Synthesis and Anticancer Activity
Letters in Drug Design & Discovery Recent Advances of mTOR Inhibitors Use in Autosomal Dominant Polycystic Kidney Disease: Is the Road Still Open?
Current Medicinal Chemistry Dynamical Behaviors of the Transcriptional Network Including REST and miR-21 in Embryonic Stem Cells
Current Bioinformatics Synthesis, Characterization, and Inducing Tumor Cell Apoptosis of Two Ru(II) Complexes Containing Guanidinium as Ligands
Anti-Cancer Agents in Medicinal Chemistry Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Proteins as Alternate Targets of Enediynes
Letters in Drug Design & Discovery Novel Aglycones of Steroidal Glycoalkaloids as Potent Tyrosine Kinase Inhibitors: Role in VEGF and EGF Receptors Targeted Angiogenesis
Letters in Drug Design & Discovery Vitamin D and Vitamin D Analogs in Cancer Treatment
Current Drug Targets The Fate of Nanocarriers As Nanomedicines In Vivo: Important Considerations and Biological Barriers to Overcome
Current Medicinal Chemistry Relevance of Drug Metabolizing Enzyme Activity Modulation by Tea Polyphenols in the Inhibition of Esophageal Tumorigenesis
Medicinal Chemistry Toxicity and Relative Biological Effectiveness of Alpha Emitting Radioimmunoconjugates
Current Radiopharmaceuticals A Review on Extraction, Synthesis and Anticancer Activity of Betulinic Acid
Current Bioactive Compounds The Analysis of the Druggable Families Based on Topological Features in the Protein-Protein Interaction Network
Letters in Drug Design & Discovery ESM-1: A Novel Tumor Biomaker and its Research Advances
Anti-Cancer Agents in Medicinal Chemistry Nanoparticles for Gene Delivery: A Brief Patent Review
Recent Patents on Drug Delivery & Formulation Vascular Endothelial Growth Factor: A New Paradigm for Targeting Various Diseases
Current Angiogenesis (Discontinued) Phytochemical, Anti-diabetic and Cardiovascular Properties of Urtica dioica L. (Urticaceae): A Review
Mini-Reviews in Medicinal Chemistry Integrin (αvβ3) Targeted RGD Peptide Based Probe for Cancer Optical Imaging
Current Protein & Peptide Science The Food-gut Human Axis: The Effects of Diet on Gut Microbiota and Metabolome
Current Medicinal Chemistry